221 related articles for article (PubMed ID: 37941971)
1. Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives.
Fraser M; Seetharamu N; Diamond M; Lee CS
Cancer Manag Res; 2023; 15():1233-1243. PubMed ID: 37941971
[TBL] [Abstract][Full Text] [Related]
2. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
3. The Current Landscape for
Desai A; Cuellar S
J Adv Pract Oncol; 2022 Jul; 13(5):539-544. PubMed ID: 35910499
[TBL] [Abstract][Full Text] [Related]
4. Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics.
Guo MZ; Marrone KA; Spira A; Waterhouse DM; Scott SC
Onco Targets Ther; 2021; 14():5321-5331. PubMed ID: 34853516
[No Abstract] [Full Text] [Related]
5. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
6. Lung Cancer with
Fujino T; Suda K; Mitsudomi T
Lung Cancer (Auckl); 2021; 12():35-50. PubMed ID: 34295201
[No Abstract] [Full Text] [Related]
7. Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation.
Brazel D; Zhang S; Nagasaka M
Lung Cancer (Auckl); 2022; 13():33-45. PubMed ID: 35592355
[TBL] [Abstract][Full Text] [Related]
8. Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib.
Tan AC; Loh TJ; Kwang XL; Tan GS; Lim KH; Tan DSW
Lung Cancer (Auckl); 2021; 12():11-20. PubMed ID: 33776501
[TBL] [Abstract][Full Text] [Related]
9. Current and future treatment options for
Hong L; Zhang J; Heymach JV; Le X
Ther Adv Med Oncol; 2021; 13():1758835921992976. PubMed ID: 33643443
[TBL] [Abstract][Full Text] [Related]
10. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
[TBL] [Abstract][Full Text] [Related]
11. The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.
Hsu R; Benjamin DJ; Nagasaka M
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509224
[TBL] [Abstract][Full Text] [Related]
12. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
[TBL] [Abstract][Full Text] [Related]
13. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
Tseng LW; Chang JW; Wu CE
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233109
[TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Mathieu LN; Larkins E; Akinboro O; Roy P; Amatya AK; Fiero MH; Mishra-Kalyani PS; Helms WS; Myers CE; Skinner AM; Aungst S; Jin R; Zhao H; Xia H; Zirkelbach JF; Bi Y; Li Y; Liu J; Grimstein M; Zhang X; Woods S; Reece K; Abukhdeir AM; Ghosh S; Philip R; Tang S; Goldberg KB; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Jan; 28(2):249-254. PubMed ID: 34344795
[TBL] [Abstract][Full Text] [Related]
15. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
[TBL] [Abstract][Full Text] [Related]
16. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
Kanemura H; Takeda M; Shimizu S; Nakagawa K
Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.
Furqan M; Karanth S; Goyal RK; Cai B; Rombi J; Davis KL; Caro N; Saliba T
Future Oncol; 2024 Apr; ():. PubMed ID: 38629593
[TBL] [Abstract][Full Text] [Related]
18. Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer.
Watari N; Yamaguchi K; Terada H; Hamai K; Masuda K; Nishimura Y; Sakamoto S; Masuda T; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Shoda H; Ishikawa N; Fujitaka K; Miyazaki K; Miyata Y; Hamada H; Awai K; Hattori N
BMC Pulm Med; 2022 Jun; 22(1):260. PubMed ID: 35773658
[TBL] [Abstract][Full Text] [Related]
19. Capmatinib for the treatment of non-small cell lung cancer.
Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
[No Abstract] [Full Text] [Related]
20. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
